Company intelligence / Profile preview

Shanghai Wellcares Biopharmaceutical

Ownership: Private
Development stage: Commercial

Overview

Shanghai Wellcares Biopharmaceutical has developed a recombinant mutant human tumor necrosis factor targeting TNFR. This drug has reached Phase 3 clinical trials for malignant ascites and has been approved in China since July 2004 for certain indications such as non-small cell lung cancer. The company focuses on enhancing the efficacy of chemotherapeutic drugs and synergistic effects with various chemotherapeutics, particularly in late-stage NSCLC and NHL patients.

Therapeutic areas: Oncology
Modalities: Recombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Shanghai Wellcares Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Wellcares Biopharmaceutical.

Explore the full profile